Pirfenidone

pirfenidone (PFD) is a new pyridinone compound with broad-spectrum anti fibrosis effect, which can prevent and reverse the formation of fibrosis and scar; It was listed by Yanno, Japan, in 2008, and has been approved by the US Food and Drug Administration. It is the first drug that has been proven to be effective for idiopathic pulmonary fibrosis (IPF) through a repeated, randomized, placebo-controlled phase III clinical trial; The drug also has a good effect on renal interstitial fibrosis, liver fibrosis and other fibrosis diseases; At the same time, it is also widely used in the phase II clinical research of kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I multiple neurofibroma, adolescent type I multiple neurofibroma and plexiform neurofibroma, diabetes with kidney disease, uterine leiomyoma, etc.